Treatment search

The Verspeeten family donates $3 million to pursue innovation and treatment at the Clinical Genome Center at LHSC – London

Although the announcement had been planned for some time, an additional $3 million donation to help fight cancer is more poignant as Archie Verspeeten’s son Ron died of cancer on Wednesday morning.

The second donation of $3 million from Archie and his late wife Irene Verspeeten brings the couple’s total donation to the Archie and Irene Verspeeten Center for Clinical Genomics at London Health Sciences Center (LHSC) to $6 million.

This donation will provide patients with access to advanced genetic testing, clinical trials and studies, allowing them to explore additional treatment options otherwise unavailable to patients with genetically complex diseases.

“The Verspeeten Clinical Genome Center at London Health Sciences Center has already had a profound impact on the lives of LHSc patients and on patient care across Ontario, the reality is that the best is yet to come,” said John MacFarlane, President and CEO of London. Health Sciences Foundation.

The story continues under the ad

“As breakthroughs in research are discovered and new treatment options are explored, the Verspeeten Clinical Genome Center has the ability to completely redefine the standard of care and how patients are treated.

“Archie and Irene’s vision and passion for finding a cure to end cancer is a driving force in making everything possible through the center.”

Read more:

“A first of its kind in Canada” – LHSC announced the Clinical Genome Center

Archie’s late wife, Irene, and his two sons, Alan and now Ron, all died of pancreatic cancer, which was the original focus of the Verspeeten Clinical Genome Center in collaboration with the Baker Center for Pancreatic Cancer. .

“As I was almost two years ago, I continue to be honored today that we are able to support a life-changing program like the Verspeeten Clinical Genome Centre,” said Archie Verspeeten. “My wife Irene and I know firsthand the cost that can come from being diagnosed with cancer. I wish that no family endures such pain and that no patient endures such suffering.

With this most recent donation, LHSC officials say they will be able to further expand proposed genetic profiling to include other known biomarkers, as well as strengthen laboratory infrastructure and epigenomic testing capabilities. .

The Archie and Irene Verspeeten Clinical Genomics Center launched in October 2020 is the first of its kind in Canada, enabling doctors to more accurately diagnose patients based on their genes, predict the course of their disease and provide new options highly targeted treatments.

The story continues under the ad

“Thanks to donor funding, we have been able to recruit a highly skilled team of researchers and scientists who are driving innovation forward,” said Dr. Bekim Sadikovic. “With the network we have created and the work already done in advanced data analysis, we have become a leader in epigenomic testing. We are truly on the cusp of something remarkable that will completely redefine the way we treat patients.

© 2022 Global News, a division of Corus Entertainment Inc.